[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584871":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":35,"locations":41,"responsibleParty":69,"collaborators":73,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":34,"enrollmentInfo":85,"targetDuration":34,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":44,"whyStopped":34,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Dr Cipto Mangunkusumo General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Potassium Channel Acid Blocker","EXPERIMENTAL","Each randomized patients will consume Tegoprazan 50 mg tab PO OD for 2 weeks",[13],"Drug: Tegoprazan",{"label":15,"type":16,"description":17,"interventionNames":18},"Proton Pump Inhibitor","ACTIVE_COMPARATOR","Each randomized patients will consume Lansoprazole 30 mg tab PO OD for 2 weeks",[19],"Drug: Lansoprazole",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tegoprazan","Tegoprazan 50 mg tab PO OD in 2 weeks",[9],[9,27],"PCAB",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Lansoprazole","Lansoprazole 30 mg tab PO OD in 2 weeks",[15],[15,33],"PPI",null,[36],{"name":37,"role":38,"phone":39,"phoneExt":34,"email":40},"Mario Steffanus MD","CONTACT","+6281288002263","mario.steffanus@atmajaya.ac.id",[42,61],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Cipto Mangunkusumo National General Hospital","RECRUITING","Jakarta","DKI Jakarta","10430","Indonesia","ID",{"type":51,"coordinates":52},"Point",[53,54],106.84513,-6.21462,{"lat":54,"lon":53},[57],{"name":58,"role":38,"phone":59,"phoneExt":34,"email":60},"Achmad Fauzi, MD","+6281386668655","ppfauzidrgm@gmail.com",{"facility":62,"status":44,"city":45,"state":46,"zip":63,"country":48,"countryCode":49,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"Atma Jaya Hospital","14440",{"type":51,"coordinates":65},[53,54],{"lat":54,"lon":53},[68],{"name":37,"role":38,"phone":39,"phoneExt":34,"email":40},{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"SPONSOR_INVESTIGATOR","Mario Steffanus","Gastroenterology and Hepatology Division Trainee",[74],{"name":5,"class":6},"100584871","tegoprazan-and-lansoprazole-effectiveness-in-bleeding-peptic-ulcer-treatment-100584871",false,"NCT06894992","Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment","A Comparison of The Effectiveness of Tegoprazan and Lansoprazole in Achieving Cure Rates in Patients With Bleeding Peptic Ulcers: A Double-Blind Randomized Trial","TALENT","Inclusion Criteria:\n\n* Subjects diagnosed with upper gastrointestinal bleeding caused by peptic ulcer through gastroscopic examination\n\nExclusion Criteria:\n\n* Allergic to Tegoprazan or Lansoprazole\n* Diagnosed with gastric or duodenal cancer, pregnant\n* History of H. pylori infection treatment failure\n* Presence of comorbidities such as chronic kidney disease or decompensated liver cirrhosis\n* Alcohol consumption\n* Undergoing chemotherapy","ALL","18 Years",{"count":86,"type":87},162,"ESTIMATED","INTERVENTIONAL",[90],"NA","The goal of this clinical trial is to compare the effects of tegoprazan vs lansoprazole in healing bleeding peptic ulcers. It will also teach about the safety of both modalities. The main questions it aims to answer are:\n\nHow does the effectiveness of Tegoprazan compare with Lansoprazole in two weeks of healing rate bleeding peptic ulcer patients in the Indonesian population?\n\nResearchers will compare the drug tegoprazan to lansoprazole with a double-blind randomized control to see their effect on healing bleeding peptic ulcers.\n\nParticipants will:\n\nTake drug tegoprazan 50 mg OD or lansoprazole 30 mg OD every day for 2 weeks Endoscopic examination at the beginning before treatment and after completion of treatment within 2 weeks Record of their adverse effect occurrence",[93],"Peptic Ulcer Bleeding",[23,29,95,93,96],"Peptic Ulcer","Healing Rate","2025-05-23",{"date":99,"type":100},"2025-05-29","ACTUAL",{"date":102,"type":100},"2025-05-01",{"date":104,"type":87},"2025-12-31",{"name":71,"class":6},2]